Table 1 Summary of recent human studies that assessed the effects of high-volume hemofiltration as a blood purification technique on hemodynamics and survival
Study | Design | Number of patients | Clinical setting | Dose, mL/kg per hour | Improved hemodynamics with HVHF | Improved survival with HVHF | P value (survival) |
|---|---|---|---|---|---|---|---|
Honoré, et al. [29] 2000 | Prospective, cohort, uncontrolled | 20 | Refractory septic shock | 115 | Yes | Yes. 28-day survival: 21% (expected) to 45% (observed) | <0.05 |
Cole, et al. [26] 2001 | Randomized, crossover | 11 | Septic shock with multi-organ failure | 6,000 mL/hour | Yes | Not assessed | N/A |
Joannes-Boyau, et al. [30] 2004 | Prospective, cohort, uncontrolled | 24 | Septic shock | 40-60 | Yes | Yes. 28-day survival: 30% (expected) to 54% (observed) | <0.075 |
Laurent, et al. [35] 2005 | RCT | 61 | Resuscitated cardiac arrest | 200 | Yes | Yes. Six-month survival: 21% to 45% | 0.026 |
Jiang, et al. [34] 2005 | RCT | 37 | Severe acute pancreatitis | 4,000 mL/hour | Yes | Yes. 14-day survival: 68.4% to 94.4% | 000000 |
Ratanarat, et al. [33] 2005 | Prospective, cohort, uncontrolled | 15 | Severe sepsis | 85 (pulse HVHF) | Yes | Yes. 28-day survival: 30% (expected) to 53% (observed) | N/A |
Piccinni, et al. [32] 2006 | Retrospective, uncontrolled | 80 | Septic shock | 45 | Yes | Yes. 28-day survival: 27.5% to 55% | 0.005 |
Cornejo, et al. [28] 2006 | Prospective, cohort, uncontrolled | 20 | Refractory septic shock | 100 | Yes | Yes. Hospital survival: 37% (expected) to 60% (observed) | <0.03 |
Boussekey, et al. [27] 2008 | RCT | 20 | Septic shock | 65 | Yes | No | 0.65 |
Zhu, et al. [77] 2009 | Retrospective | 63 | Severe acute pancreatitis | 60-80 | No | Yes. 28-day survival: 65.5% to 91.2% | 0.014 |
IVOIRE study, ongoing | RCT | Approximately 150 | Septic shock | 70 | Not reported | Not reported | Not reported |